Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: An Adoptive Cellular Therapy for Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From Matched HLA Donors

NCT06572631 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06572631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06572631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: An Adoptive Cellular Therapy for Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From Matched HLA Donors
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Withdrawn
Start date
June 7, 2025
Completion date
December 12, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory myelodysplastic syndrome